Leland Stanford Junior University

Aravive Biologics, Inc.

Auckland Uniservices Limited

Ruga Corporation

Other

Akso Biopharmaceutical, Inc.

Bluelink Pharmaceuticals, Inc.

Amato J Giaccia

William Alexander Denny

Mihalis S Kariolis

Yu Rebecca Miao

Douglas Scott Jones

Jennifer R Cochran

Katherine Cynthia Fuh

Erinn Bruno Rankin

Denise Chan

Connie L Sun

Michael Patrick Hay

Raymond Tabibiazar

Muriel Bonnet

John Martin Brown

Nigel P Minton

Todd A Aguilera

Edwin Lai

Olga Razorenova

Po-wai Yuen

Ray Tabibiazar

Susan Hershenson

Joseph C Wu

Albert C Koong

John Irwin

Mei Huang

George M Hahn

Alie H Saad

Patrick Sutphin

Patrick O'Connor

Sandra Turcotte

Zhong Yun

Shie-Chau Liu

Kaushik Thakkar

Xin Eric Zhang

Jeanne Noe

Hanna Sanoff

Joel E Tepper

Mihalis Kariolis

Andrew Z Wang

Anna Claire Giddens

Katherine Fuh

Yu Miao

Douglas Jones

The invention is directed to novel sPD-1 variant&#x2014;Fc fusion proteins.

SPD-1 variant# FC fusion proteins

Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide can inhibit the activity of PD-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type PD-1 and one or more of its ligands, PD-L1 and PD-L2.

Receptor-based antagonists of the programmed cell death 1 (PD-1) pathway

Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy

Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

Antifibrotic activity of GAS6 inhibitor

Compositions and methods are provided for alleviating endometriosis, kidney disease, inflammatory disease and/or transplant rejection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis

Provided herein are Substituted Benzamides, compositions, and method of their manufacture and use.

Substituted benzamides and their uses

Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.

Inhibition of AXL signaling in anti-metastatic therapy

The present invention provides methods for inhibiting growth and proliferation of HIF pathway proficient cells by administering GLUT1 inhibitors of the invention to HIF pathway proficient cells.

Synthetic lethal targeting of glucose transport

Short hairpin RNA (shRNA) interference therapy targeting hypoxia inducible factor&#x2014;lot (HIF-1 &#x3b1;) prolyl-4-hydroxylase protein (HIF-PHD2) is used for treatment of myocardial ischemia. This treatment can be followed noninvasively by molecular imaging. Provided are compositions comprising novel vectors encoding shRNA targeting the HIF-1&#x3b1; and asparaginyl hydroxylase genes. The vectors encoding shRNA are also useful for the treatment of cardiac diseases, peripheral vascular diseases and decubitis ulcers.

ShRNA gene therapy for treatment of ischemic heart disease

According to the disclosure hypoxia-mediated adipogenic inhibition involves the repression of PPAR&#x3b3;2 expression and its activity is a common mechanism for adipogenic inhibition by a variety of stimuli. The present disclosure relates to methods and compositions for regulating adipogenesis. The disclosure provides compositions comprising one or more DEC1/Stra13 fragments of capable of inhibiting PPAR&#x3b3;2 promoter activity. These fragments, e.g. the basic helix loop helix domain or amino acids 1-141, have substantially the same PPAR&#x3b3;2 promoter repressing activity as the full length polypeptide. The present disclosure provides methods of inhibiting adipogenesis comprising contacting a cell with a fragment of DEC1/Stra13. The invention further relates to methods and compositions of inhibiting angiogenesis in a tumor comprising contacting a tumor or tumor cell with a DEC1/Stra13 agonist.

Methods and compositions for regulating adipogenesis

Growing community of inventors

Stanford, CA, United States of America

Amato J Giaccia